---
title: "Iterum Therapeutics Received Notice of Delisting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281174211.md"
description: "Iterum Therapeutics has received a notice from Nasdaq regarding the delisting of its ordinary shares due to the withdrawal of its appeal against a previous delisting decision. This decision was made because the company failed to maintain the required minimum bid price of $1.00. Trading will be suspended on April 1, 2026, and a Form 25-NSE will be filed to officially remove the shares from Nasdaq."
datetime: "2026-03-31T11:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281174211.md)
  - [en](https://longbridge.com/en/news/281174211.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281174211.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/281174211.md) | [繁體中文](https://longbridge.com/zh-HK/news/281174211.md)


# Iterum Therapeutics Received Notice of Delisting

On March 30, 2026, Nasdaq notified the company that its ordinary shares will be delisted after it withdrew its appeal of a prior delisting determination stemming from failure to maintain the $1.00 minimum bid price. Trading will be suspended at the open on April 1, 2026, and a Form 25-NSE will be filed to remove the shares from Nasdaq.

Original SEC Filing: Iterum Therapeutics plc \[ ITRM \] - 8-K - Mar. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [Iterum Therapeutics plc (ITRM.US)](https://longbridge.com/en/quote/ITRM.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ITERUM THERAPEUTICS PLC (ITRMF.US)](https://longbridge.com/en/quote/ITRMF.US.md)

## Related News & Research

- [Iterum Therapeutics Files Wind Up Petition; Shares Shoot In Pre-market](https://longbridge.com/en/news/280999380.md)
- [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/en/news/281024362.md)
- [Arcutis Reports New Positive Phase 2 Results For ZORYVE Cream In Infant Atopic Dermatitis](https://longbridge.com/en/news/280971278.md)
- [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/en/news/281015927.md)
- [Insmed Sees Rising Physician Adoption of Brinsupri, Morgan Stanley Says](https://longbridge.com/en/news/281049788.md)